VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Choueiri on Trials Investigating Combination Regimens for RCC

Toni K. Choueiri, MD
Published: Monday, Aug 07, 2017



Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses trials investigating combinations for patients with renal cell carcinoma (RCC).

There is a promising phase III trial combining axitinib (Inlyta) with pembrolizumab (Keytruda), explains Choueiri. The preliminary data from the phase I trial showed a high response rate of 71% for patients with RCC.

Additionally, there is a phase I study investigating the combination of lenvatinib (Lenvima) plus pembrolizumab, which has shown exciting activity, states Choueiri. This combination will also be compared with levantinib plus everolimus (Afinitor) in patients with RCC.
 


Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses trials investigating combinations for patients with renal cell carcinoma (RCC).

There is a promising phase III trial combining axitinib (Inlyta) with pembrolizumab (Keytruda), explains Choueiri. The preliminary data from the phase I trial showed a high response rate of 71% for patients with RCC.

Additionally, there is a phase I study investigating the combination of lenvatinib (Lenvima) plus pembrolizumab, which has shown exciting activity, states Choueiri. This combination will also be compared with levantinib plus everolimus (Afinitor) in patients with RCC.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x